title: An update on biomarkers of heart failure in hypertensive patients.
abstract: Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes.
authors: Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Poland.
authors: Anna
authors: A
authors: Gluba
authors: Agata
authors: A
authors: Bielecka-Dabrowa
authors: Agata
authors: A
authors: Bielecka
authors: Dimitri P
authors: DP
authors: Mikhailidis
authors: Nathan D
authors: ND
authors: Wong
authors: Stanley S
authors: SS
authors: Franklin
authors: Jacek
authors: J
authors: Rysz
authors: Maciej
authors: M
authors: Banach
mesh_terms: D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000378:metabolism*